Literature DB >> 8387988

Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials.

J R Simpson1, J Horton, C Scott, W J Curran, P Rubin, J Fischbach, S Isaacson, M Rotman, S O Asbell, J S Nelson.   

Abstract

PURPOSE: The influence of tumor site, size, and extent of surgery on the survival of patients with glioblastoma multiforme treated on three consecutive prospectively randomized Radiation Therapy Oncology Group trials employing surgery and irradiation plus or minus chemotherapy was studied. METHODS AND MATERIALS: Six hundred forty-five patients with a diagnosis of glioblastoma multiforme on central pathological review were analyzed for survival with respect to known prognostic factors, that is, age and Karnofsky Performance Status, as well as extent of surgery, site, and size. Surgical treatment consisted of biopsy only in 17%, partial resection in 64%, and total resection in 19%. Tumors were located in frontal lobe in 43%, temporal lobe in 28%, and parietal lobe in 25%. Maximum tumor diameter as determined on computed tomography or magnetic resonance imaging scans was less than 5 cm for 38%, between 5-10 cm for 56% and greater than 10 cm for 6% of patients. The extent of surgical therapy was the same for tumors greater than 5 or greater than 10 cm, whereas total resection was more often performed for tumors less than 5 cm. The extent of surgery did not appear to vary with age or site.
RESULTS: Patients undergoing total resection had a median survival of 11.3 months compared to 6.6 months for patients with a biopsy only. A significant difference in median survival was also found for partial resection versus biopsy only treatment (10.4 vs. 6.6 months). There was no difference in survival for the different tumor sizes. Patients with frontal lobe tumors survived longer than those with temporal or parietal lobe lesions (11.4 months, 9.1 months, and 9.6 months, respectively) (p = 0.01). A Cox multivariate model confirmed a significant correlation of age, Karnofsky Performance Status, extent of surgery, and primary site with survival. The best survival rates occurred in patients who had at least three of the following features: < 40 years of age, high Karnofsky Performance Status, frontal tumors, and total resection (17 months median).
CONCLUSION: We conclude that biopsy only yields inferior survival to more extensive surgery for patients with glioblastoma multiforme treated with surgery and radiation therapy.

Entities:  

Mesh:

Year:  1993        PMID: 8387988     DOI: 10.1016/0360-3016(93)90203-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  133 in total

Review 1.  Optimizing glioblastoma resection: intraoperative mapping and beyond.

Authors:  Joseph A Osorio; Manish K Aghi
Journal:  CNS Oncol       Date:  2014

Review 2.  Brain tumours: classification and genes.

Authors:  V P Collins
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

3.  Central nervous system cancers.

Authors:  Louis Burt Nabors; Mario Ammirati; Philip J Bierman; Henry Brem; Nicholas Butowski; Marc C Chamberlain; Lisa M DeAngelis; Robert A Fenstermaker; Allan Friedman; Mark R Gilbert; Deneen Hesser; Matthias Holdhoff; Larry Junck; Ronald Lawson; Jay S Loeffler; Moshe H Maor; Paul L Moots; Tara Morrison; Maciej M Mrugala; Herbert B Newton; Jana Portnow; Jeffrey J Raizer; Lawrence Recht; Dennis C Shrieve; Allen K Sills; David Tran; Nam Tran; Frank D Vrionis; Patrick Y Wen; Nicole McMillian; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2013-09-01       Impact factor: 11.908

4.  Identifying Voxels at Risk for Progression in Glioblastoma Based on Dosimetry, Physiologic and Metabolic MRI.

Authors:  Mekhail Anwar; Annette M Molinaro; Olivier Morin; Susan M Chang; Daphne A Haas-Kogan; Sarah J Nelson; Janine M Lupo
Journal:  Radiat Res       Date:  2017-07-19       Impact factor: 2.841

5.  Phase I study of topotecan in combination with concurrent radiotherapy in adults with glioblastoma.

Authors:  Thierry Lesimple; Mohammed B Hassel; Daniel Gédouin; Eric Seigneuret; Béatrice Carsin; Abderrahmane Hamlat; Laurent Riffaud; Hélène Simon; Jean P Malhaire; Yvon Guégan
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

6.  Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience.

Authors:  Maria Teresa Solomon; Nederlay Miranda; Eugenia Jorrín; Ivonne Chon; Jorge Juan Marinello; José Alert; Patricia Lorenzo-Luaces; Tania Crombet
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

7.  High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas.

Authors:  John M Watkins; David T Marshall; Sunil Patel; Pierre Giglio; Amy E Herrin; Elizabeth Garrett-Mayer; Joseph M Jenrette
Journal:  J Neurooncol       Date:  2009-01-14       Impact factor: 4.130

8.  Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients.

Authors:  Uwe Pichlmeier; Andrea Bink; Gabriele Schackert; Walter Stummer
Journal:  Neuro Oncol       Date:  2008-07-30       Impact factor: 12.300

Review 9.  Controversies concerning the application of brachytherapy in central nervous system tumors.

Authors:  Bo-Lin Liu; Jin-Xiang Cheng; Xiang Zhang; Wei Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2010-02       Impact factor: 4.553

10.  Supratentorial glioblastoma: neuroradiological findings and survival after surgery and radiotherapy.

Authors:  A Pierallini; M Bonamini; M F Osti; P Pantano; F Palmeggiani; A Santoro; R Maurizi Enrici; L Bozzao
Journal:  Neuroradiology       Date:  1996-05       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.